BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20737514)

  • 21. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
    J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy.
    Koralnik IJ; Boden D; Mai VX; Lord CI; Letvin NL
    Neurology; 1999 Jan; 52(2):253-60. PubMed ID: 9932940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.
    Reid CE; Li H; Sur G; Carmillo P; Bushnell S; Tizard R; McAuliffe M; Tonkin C; Simon K; Goelz S; Cinque P; Gorelik L; Carulli JP
    J Infect Dis; 2011 Jul; 204(2):237-44. PubMed ID: 21673034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
    Phan-Ba R; Lommers E; Tshibanda L; Calay P; Dubois B; Moonen G; Clifford D; Belachew S
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH; Moraes L; Fink MC; Callegaro D; Romano CM; Oliveira AC
    Arq Neuropsiquiatr; 2014 Dec; 72(12):960-5. PubMed ID: 25465776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
    Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.
    Mancuso R; Saresella M; Hernis A; Marventano I; Ricci C; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2012 Dec; 10():248. PubMed ID: 23232085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
    Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
    Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the management of PML: focus on natalizumab.
    Fox R
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.
    Iacobaeus E; Ryschkewitsch C; Gravell M; Khademi M; Wallstrom E; Olsson T; Brundin L; Major E
    Mult Scler; 2009 Jan; 15(1):28-35. PubMed ID: 18805840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma.
    Plavina T; Berman M; Njenga M; Crossman M; Lerner M; Gorelik L; Simon K; Schlain B; Subramanyam M
    J Clin Virol; 2012 Jan; 53(1):65-71. PubMed ID: 22104399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
    Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
    Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.
    Outteryck O; Ongagna JC; Duhamel A; Zéphir H; Collongues N; Lacour A; Fleury MC; Berteloot AS; Blanc F; Giroux M; Vermersch P; de Sèze J
    J Neurol; 2012 Nov; 259(11):2293-8. PubMed ID: 22527227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
    Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
    Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease-modifying drugs for multiple sclerosis and JC virus expression.
    Miller CS; Houff SA; Hopper J; Danaher RJ; Gurwell JA; Lin Y; Vega N; Berger JR
    J Neurovirol; 2012 Oct; 18(5):411-5. PubMed ID: 22585288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
    Mazda ME; Brosch JR; Wiens AL; Bonnin JM; Kamer AP; Mattson DH; Snook RJ
    Int J Neurosci; 2013 May; 123(5):353-7. PubMed ID: 23252596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.